Sternocleidomastoid Thickness in Sarcopenia

Could Changes in Sternocleidomastoid Muscle Thickness be a Predictor of Sarcopenia in Intensive Care Patients?

In order to prevent sarcopenia in intensive care patients and to guide nutritional therapy, evaluation of muscle thickness with ultrasonography is a modern, simple and non-invasive procedure routinely performed by Anesthesiology and Reanimation specialists. Sarcopenia in intensive care patients has been demonstrated in many studies. It has been studied that routine examination of changes in rectus femoris muscle thickness by ultrasonography is a predictor of sarcopenia. However, the muscles in the neck region, such as the sternocleidomastoid muscle, which are easy to examine, have not been studied very well. There is no study in the literature with the sternocleidomastoid muscle. For this reason, we decided to examine the relationship of sternocleidomastoid muscle thickness with patient characteristics, treatments, feeding route and type, feeding time, length of stay in intensive care unit, as in routine measurements of rectus femoris muscle thickness by ultrasonography.

Study Overview

• Status: Recruiting
• Conditions: Sarcopenia
• Intervention / Treatment: Diagnostic test: Muscle thickness measurement

Detailed Description

Sarcopenia is an important clinical condition, characterized by a decrease in muscle mass and function that increases with age, especially in elderly patients. Studies have shown that sarcopenic patients have higher morbidity and mortality rates than non-sarcopenic patients. Along with the increased risk of muscle wasting in intensive care patients, there is an increase in both hospital mortality rates and the frequency of post-hospital mobilization problems.

Intensive care patients are a group of patients who are very prone to protein-energy malnutrition, and this leads to complications such as nosocomial infection and multiple organ failure, leading to prolongation of the stay in the intensive care unit, as well as an increase in morbidity and mortality. Therefore, nutritional support is a routine requirement of intensive care treatment and has a vital role in the prevention and treatment of nutritional deficiencies in intensive care patients.

The first point that should be evaluated in terms of the follow-up of a patient on whom nutritional support is maintained is to know for what reason, when, and what kind of treatment is planned in terms of quality and quantity. This is a starting point for monitoring. Knowing the patient's clinical and laboratory values when nutritional therapy is initiated allows the evaluation of how these data have changed during follow-up. The purpose of assessment of nutritional status is to identify the type and degree of malnutrition in order to make a rational treatment approach. However, there is no test that is both sensitive and specific to determine malnutrition in intensive care patients.

• Study Type: Observational
• Enrollment (Estimated): 80

Contacts and Locations

• Study Contact: Name: Onur Baran, Asst. Prof.; Phone Number: 05393422582; Email: dronurbaran@hotmail.com

Study Locations

• Turkey
  • Tekirdağ, Turkey
    • Recruiting
    • Tekirdag Namik Kemal University
    • Contact: Onur Baran, Asst. Prof.; Phone Number: +905393422582; Email: dronurbaran@hotmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Patients who are expected to be followed up in the intensive care unit for at least 1 week in a tertiary university research and education hospital based 11 bed ICU

Description

Inclusion Criteria:

• Patients who are expected to be followed up in the intensive care unit for at least 1 week
• Patients over 18 years old

Exclusion Criteria:

• Patients under 18 years of age
• Head-neck, femur trauma patients
• Those with a diagnosis of primary neuromuscular disease
• Those who have a condition that prevents imaging in the body parts where ultrasonography is planned

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Muscle thickness measurement; Rectus femoris and sternocleidomastoideus muscle thickness will be measured via ultrasonography	Diagnostic test: Muscle thickness measurement; Rectus femoris and sternocleidomastoideus muscle thickness will be measured via ultrasonography in admission and on 7th day of admission

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Muscle thickness	Rectus femoris and Sternocleidomastoideus muscle thickness change when compared to the value measured at admission to the intensive care unit.	1 week

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Nutrition regime	Nutrition regimes, calorie and protein intake during admission will be saved.	1week
Nutrition Scores	NRS 2002, NUTRIC scores will be calculated in admission	Day 1

Collaborators and Investigators

• Sponsor: Namik Kemal University
• Investigators: Study Director: Onur Baran, Asst. Prof., Department of Anesthesiology and Reanimation, Tekirdağ Namık Kemal University, Tekirdağ, Turkey; Principal Investigator: Ayhan Şahin, Asst. Prof., Department of Anesthesiology and Reanimation, Tekirdağ Namık Kemal University, Tekirdağ, Turkey; Study Chair: Cavidan Arar, Prof., Department of Anesthesiology and Reanimation, Tekirdağ Namık Kemal University, Tekirdağ, Turkey

Publications and helpful links

General Publications

• Kizilarslanoglu MC, Kuyumcu ME, Yesil Y, Halil M. Sarcopenia in critically ill patients. J Anesth. 2016 Oct;30(5):884-90. doi: 10.1007/s00540-016-2211-4. Epub 2016 Jul 4.
• Rustani K, Kundisova L, Capecchi PL, Nante N, Bicchi M. Ultrasound measurement of rectus femoris muscle thickness as a quick screening test for sarcopenia assessment. Arch Gerontol Geriatr. 2019 Jul-Aug;83:151-154. doi: 10.1016/j.archger.2019.03.021. Epub 2019 Mar 27.

Helpful Links

• Reference

Study record dates

Study Major Dates

• Study Start (Actual): July 15, 2023
• Primary Completion (Estimated): February 15, 2024
• Study Completion (Estimated): February 28, 2024

Study Registration Dates

• First Submitted: June 23, 2023
• First Submitted That Met QC Criteria: June 23, 2023
• First Posted (Actual): July 3, 2023

Study Record Updates

• Last Update Posted (Actual): August 1, 2023
• Last Update Submitted That Met QC Criteria: July 28, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Keywords: intensive care; sarcopenia; ultrasonography
• Additional Relevant MeSH Terms: Nervous System Diseases; Neurologic Manifestations; Neuromuscular Manifestations; Pathological Conditions, Anatomical; Muscular Atrophy; Atrophy; Sarcopenia
• Other Study ID Numbers: 2022.67.04.17

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No